Review
Immunology
Qingxiao Song, Ubaydah Nasri, Defu Zeng
Summary: This review provides an overview of the current understanding of the pathogenesis of steroid-refractory gut graft-versus-host disease, advanced technologies for human studies, and potential novel therapeutic options.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Shuang Fan, Wen-Xuan Huo, Yang Yang, Meng-Zhu Shen, Xiao-Dong Mo
Summary: This study reports the updated results of ruxolitinib as treatment for SR-GVHD and compares the efficacy and safety between children and adults. The findings suggest that ruxolitinib is an effective and safe treatment for SR-GVHD, and both children and adults can benefit from it.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Surgery
Justine Khodr, Philippe Zerbib, Moshe Rogosnitzky, Leonardo Magro, Stephanie Truant, Ibrahim Yakoub-Agha, Alain Duhamel, David Seguy
Summary: For patients with severe GI-aGVHD, consideration should be given to DE surgery when resistance to corticosteroids is identified. Data shows a significant improvement in survival rate after DE operation, with a trend towards reducing sepsis-related mortality.
Review
Immunology
Makoto Murata, Takanori Teshima
Summary: This article discusses the potential of MSC therapy in the treatment of acute GVHD, along with a comparison of studies on the two products, Remestemcel-L and Temcell. While Temcell's real-world efficacy was found to be equivalent to that observed in a prospective study, the precise position of Remestemcel-L/Temcell therapy in the treatment of acute GVHD remains to be determined.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Fateeha Furqan, Kwang W. Ahn, Yue Chen, Manmeet Kaur, Syed A. Abutalib, Nausheen Ahmed, Sairah Ahmed, Mohamed A. Kharfan-Dabaja, Johnathan Friedberg, Tara Gregory, LaQuisa Hill, Cole Sterling, Stephan K. Barta, Mazyar Shadman, Miguel-Angel Perales, Jasmine Zain, Alex F. Herrera, Craig Sauter, Mehdi Hamadani
Summary: This study evaluated the outcomes of allo-HCT in patients with relapsed/refractory ALCL and found that it can result in durable disease control in a significant proportion of patients. However, refractory disease and racial minority status predicted inferior outcomes after allo-HCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medicine, General & Internal
Hengwei Wu, Jimin Shi, Yi Luo, Yamin Tan, Mingming Zhang, Xiaoyu Lai, Jian Yu, Lizhen Liu, Huarui Fu, He Huang, Yanmin Zhao
Summary: In this study, the clinical response to ruxolitinib in patients with steroid-refractory chronic graft-vs-host disease after allogeneic hematopoietic stem cell transplantation was investigated, and its safety profile was evaluated during the treatment course. The majority of patients treated with ruxolitinib showed significant treatment responses with a relatively well-tolerated safety profile, with lung involvement and matched related donors being associated with less favorable treatment response.
Article
Cell & Tissue Engineering
Dong Won Baek, Hee Jeong Cho, Ju-Hyung Kim, Jae Sook Ahn, Hyeoung-Joon Kim, Sung Nam Lim, Jun Won Cheong, Sung-Yong Kim, Ho Sup Lee, Jong Ho Won, Ho-Young Yhim, Sang Kyun Sohn, Joon Ho Moon
Summary: In this study, the safety and efficacy of imatinib in patients with steroid-resistant chronic graft-versus-host disease (cGVHD) were evaluated. The results showed that imatinib had significant therapeutic effects on the disease, reducing its severity and improving the quality of life for patients.
CELL TRANSPLANTATION
(2022)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study retrospectively evaluated the effects of ruxolitinib compared with basiliximab for steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had higher overall response and complete response rates, as well as lower incidence of chronic GVHD. Ruxolitinib also improved overall survival and failure-free survival rates. In addition, ruxolitinib significantly reduced the occurrence of EBV viremia. Therefore, ruxolitinib should be recommended for the treatment of SR-aGVHD.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Jiapei Liu, Zhiping Fan, Na Xu, Jieyu Ye, Yanqiu Chen, Ruoyang Shao, Yiming Sun, Qiaoyuan Wu, Qifa Liu, Hua Jin
Summary: This study evaluated the effects of ruxolitinib compared with basiliximab in the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). The results showed that ruxolitinib had a higher overall response rate and effectively prevented chronic GVHD (cGVHD), leading to improved survival rates.
ANNALS OF HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jaroslaw Dybko, Malgorzata Sobczyk-Kruszelnicka, Sebastian Makuch, Siddarth Agrawal, Krzysztof Dudek, Sebatian Giebel, Lidia Gil
Summary: This study compared the outcomes of patients who received post-transplant cyclophosphamide (PTCy) or conventional immunosuppressants after allogeneic hematopoietic cell transplantation. The study found that patients receiving PTCy had lower rates of acute graft-versus-host disease and cytomegalovirus reactivation, and higher survival rates. Further research with a larger sample size is needed to confirm these results.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Chemistry, Medicinal
Cong Wei, Xiaoting Zhang, Dan Liang, Jilong Yang, Jingwen Du, Chunyan Yue, Lan Deng
Summary: Ruxolitinib has been shown to be a safe and effective treatment for steroid-refractory GVHD in a Chinese population, with high overall response rates in acute GVHD patients and comparable overall survival rates between responders and non-responders in chronic GVHD patients. Common adverse events include cytopenia, cytomegalovirus reactivation, and infections, particularly in patients with acute GVHD.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2021)
Article
Hematology
Francesca del Bufalo, Marco Becilli, Chiara Rosignoli, Biagio De Angelis, Mattia Algeri, Linda Hanssens, Monica Gunetti, Stefano Iacovelli, Giuseppina Li Pira, Elia Girolami, Giovanna Leone, Stefania Lazzaro, Valentina Bertaina, Matilde Sinibaldi, Stefano Di Cecca, Laura Iaffaldano, Annette Kunkele, Emilia Boccieri, Giada Del Baldo, Daria Pagliara, Pietro Merli, Roberto Carta, Concetta Quintarelli, Franco Locatelli
Summary: Autologous CD19-directed CAR-T cells have shown remarkable efficacy in children with relapsed/refractory BCP-ALL. However, patients who relapse after allo-HSCT or have lymphopenia and rapidly progressing disease face challenges in accessing autologous products. In this study, allogeneic donor-derived CD19 CAR-T cells were tested and found to effectively treat highly refractory BCP-ALL without increased toxicity compared to autologous CAR-T cells.
Article
Hematology
Sameem Abedin, Nahid Rashid, Mark Schroeder, Rizwan Romee, Mary Nauffal, Muhamad Alhaj Moustafa, Mohamed A. Kharfan-Dabaja, Jeanne Palmer, William Hogan, Mehrdad Hefazi, Samantha Larson, Shernan Holtan, Zachariah DeFilipp, Reena Jayani, Bhagirathbhai Dholaria, Joseph Pidala, Farhad Khimani, Michael R. Grunwald, Candace Butler, Mehdi Hamadani
Summary: Among 307 patients with SR-aGVHD, approximately 1/5 of patients showed resistance or intolerance to Ruxolitinib. The overall response rate to additional therapy was 36% in resistant patients with a median survival of 21 days; while 50% of intolerant patients continued to improve with additional therapy, with a median survival of 50 days. These data provide a baseline for future studies on SR-aGVHD.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Jennifer S. Whangbo, Sarah Nikiforow, Haesook T. Kim, Jonathan Wahl, Carol G. Reynolds, Sharmila C. Rai, Soomin Kim, Andrew Burden, Ana C. Alho, Joao F. Lacerda, Edwin P. Alyea III, Corey S. Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz, John Koreth
Summary: The combination of Treg-enriched lymphocytes and LD IL-2 shows promise for the treatment of steroid-refractory cGVHD, with partial responses observed in a subset of patients.
Article
Medicine, Research & Experimental
Erika S. Varady, L. Angel Ayala, Pauline U. Nguyen, Vanessa M. Scarfone, Alborz Karimzadeh, Cuiwen Zhou, Xiyu Chen, Scott A. Greilach, Craig M. Walsh, Matthew A. Inlay
Summary: Donor cell conditioning with the glucocorticoid fluticasone propionate (FLU) prior to transplantation increases HSC engraftment and reduces the severity and incidence of graft-versus-host disease (GvHD) in allogeneic hosts.
EMBO MOLECULAR MEDICINE
(2023)
Letter
Biophysics
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Hannah Choe, Peter Dawson, Andrew C. Harris, Eric van Hooren, Willem Klaassen, Eric Leifer, Margaret L. MacMillan, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Phuong Vo, John E. Levine
BONE MARROW TRANSPLANTATION
(2022)
Review
Hematology
Binod Dhakal, Saurabh Chhabra, Bipin N. Savani, Mehdi Hamadani
Summary: CAR T-cell therapy shows promise in haematological malignancies, but the complexity of autologous CAR T-cell therapy poses logistical challenges. Allogeneic effector cells offer potential solutions, but challenges such as alloreactivity need to be addressed for their widespread use.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Ajay K. Nooka, Uma Shanmugasundaram, Narayana Cheedarla, Hans Verkerke, Venkata V. Edara, Rajesh Valanparambil, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Maryam Azeem, Julia Manalo, Jeffrey M. Switchenko, Andres Chang, Susanne L. Linderman, John D. Roback, Kavita M. Dhodapkar, Rafi Ahmed, Mehul S. Suthar, Andrew S. Neish, Madhav Dhodapkar
Summary: For patients with multiple myeloma, the ability of vaccine-induced antibodies to neutralize SARS CoV-2 or its variants varies and may be influenced by factors such as race, disease, and treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Letter
Oncology
Michael Slade, Thomas G. Martin, Nitya Nathwani, Mark A. Fiala, Michael P. Rettig, Feng Gao, Abhinav Deol, Francis K. Buadi, Jonathan L. Kaufman, Craig C. Hofmeister, Tara K. Gregory, Jesus Berdeja, Ajai Chari, Ashley Rosko, Ravi Vij
Letter
Hematology
Fateeha Furqan, Morgan Maring, Aniko Szabo, Timothy S. Fenske, Mehdi Hamadani, Nirav N. Shah
Letter
Oncology
Kathryn T. T. Maples, Kevin H. H. Hall, Nisha S. S. Joseph, Craig C. C. Hofmeister, Vikas Gupta, Madhav V. V. Dhodapkar, Jonathan L. L. Kaufman, Ajay K. K. Nooka, Sagar Lonial
BLOOD CANCER JOURNAL
(2023)
Article
Biophysics
Shanze Arshad, Xi Fang, Kwang W. Ahn, Manmeet Kaur, Michael Scordo, Craig S. Sauter, Fateeha Furqan, Farrukh T. Awan, Mehdi Hamadani
Summary: This retrospective study evaluated the impact of thiotepa dose intensity on autologous stem cell transplant outcomes in adult primary central nervous system diffuse large B-cell lymphoma (PCNSL) patients. It was found that the intensity of thiotepa dose did not affect the outcomes of ASCT in PCNSL patients.
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C. Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Leifer, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Matthias Stelljes, Walter van der Velden, Emanuele Ammatuna, David Beauvais, Jerome Cornillon, Richard T. Maziarz, Johannes Schetelig, Jennifer Romeril, Margaret L. MacMillan, John E. Levine, Gerard Socie
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Mehdi Hamadani, Morton Coleman, Ralph Boccia, Juraj Duras, Martin Hutchings, Pier Luigi Zinzani, Raul Cordoba, Mariana Bastos Oreiro, Vanessa Williams, Huiqing Liu, Michael Stouffs, Peter Langmuir, Juan-Manuel Sancho
Summary: The combination of parsaclisib with obinutuzumab and bendamustine showed promising clinical benefit in patients with relapsed or refractory follicular lymphoma, without unexpected safety events.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Hematology
Alberto Mussetti, Abraham S. Kanate, Tao Wang, Meilun He, Mehdi Hamadani, Herve Finel, Ariane Boumendil, Bertram Glass, Luca Castagna, Alida Dominietto, Joseph McGuirk, Didier Blaise, Zafer Gulbas, Jose Diez-Martin, Steven G. E. Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Peter Dreger, Mei-Jie Zhang, Stephen R. Spellman, Stephanie J. Lee, Yung-Tsi Bolon, Anna Sureda
Summary: When comparing the outcomes of using a haploidentical donor and a matched unrelated donor (MUD) for lymphoma patients receiving post-transplantation cyclophosphamide (PTCy) graft-versus-host disease (GVHD) prophylaxis, the study found that MUD had better results in terms of overall mortality, progression-free survival, nonrelapse mortality, platelet engraftment, acute grade 2-4 GVHD incidence, and chronic GVHD. However, there were no significant differences in terms of relapse and neutrophil engraftment. Therefore, if a MUD is available in a timely manner, it should be preferred over a haploidentical donor for lymphoma patients using PTCy-based GVHD prophylaxis.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Letter
Oncology
Sara A. Scott, Ellen M. Marin, Kathryn T. Maples, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Nausheen Ahmed, Ambuj Kumar, Mohamed A. Kharfan-Dabaja, Zachariah DeFilipp, Alex Herrera, Shahrukh Hashmi, Bhagirathbhai Dholaria, Miguel-Angel Perales, Paul A. Carpenter, Mehdi Hamadani
Summary: Chimeric antigen receptor T-cell therapy (CAR-T) is a significant advancement in managing aggressive relapsed or refractory B-cell lymphomas, but frequent relapses remain a major challenge. There is substantial variability in assessing and managing post-CAR-T failures across transplantation and cellular therapy programs. A survey was conducted among lymphoma, transplantation, and cellular therapy physicians in the United States to determine their practice patterns for the detection, diagnosis, and management of CAR-T failure in diffuse large B-cell lymphoma. The survey revealed significant differences in surveillance, diagnosis, and treatment approaches for CAR-T failure.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Hematology
Miguel-Angel Perales, Larry D. Anderson, Tania Jain, Saad S. Kenderian, Olalekan O. Oluwole, Gunjan L. Shah, Jakub Svoboda, Mehdi Hamadani
Summary: Three CD19-directed CAR T cell therapies have been approved for second-line treatment of relapsed/refractory aggressive diffuse large B cell lymphoma. Different clinical trials have shown significant improvement with CD19 CAR T cells in second-line therapy, but there are still differences in treatment outcomes.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Review
Hematology
Fateeha Furqan, Mehdi Hamadani
Summary: Loncastuximab tesirine-lpyl has shown selectivity and efficacy in the treatment of relapsed or refractory lymphoma. It has demonstrated good safety and tolerability in clinical trials and has been approved by the US FDA.
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2022)
Article
Hematology
Mehdi Hamadani, Maud Ngoya, Anna Sureda, Qaiser Bashir, Carlos Alejandro Litovich, Herve Finel, Yue Chen, Ariane Boumendil, Jasmine Zain, Luca Castagna, Amanda F. Cashen, Didier Blaise, Mazyar Shadman, Rocco Pastano, Farhad Khimani, Mutlu Arat, Sascha Dietrich, Norbert Schmitz, Bertram Glass, Mohamed A. Kharfan-Dabaja, Paolo Corradini, Craig S. Sauter, Silvia Montoto, Mi Kwon, Alex F. Herrera, Peter Dreger
Summary: This study evaluated the outcomes of different types of allo-HCT in mature T-cell lymphomas and found no significant differences in survival and progression between the different groups. Results suggest that haplo-HCT can be comparable to matched sibling donor HCT.